Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | NRP1 | O14786 | 1/20 | 0.43 |
| ▸ | ARG1 | P05089 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322567 | 0.87 | DPP4 (0.52) | DPP4DPP8DPP9CYP1A2GLA | |
| SCHEMBL24323563 | 0.86 | DPP4 (0.54) | DPP4DPP8DPP9 | |
| SCHEMBL29390523 | 0.81 | DPP4 (0.68) | DPP4DPP8DPP9CYP1A2GLA | |
| SCHEMBL24322903 | 0.81 | DPP4 (0.42) | DPP4DPP8DPP9NRP1 | |
| SCHEMBL29350954 | 0.77 | DPP4 (0.63) | DPP4DPP8DPP9CYP1A2GLA | |
| SCHEMBL24323544 | 0.71 | DPP4 (0.63) | DPP4DPP8DPP9CYP1A2GLA | |
| SCHEMBL24322713 | 0.70 | DPP4 (0.53) | DPP4 | |
| SCHEMBL24324253 | 0.70 | DPP4 (0.55) | DPP4DPP8DPP9CYP1A2GLA | |
| SCHEMBL24322510 | 0.70 | DPP4 (0.55) | DPP4DPP8DPP9CYP1A2GLA | |
| SCHEMBL30277613 | 0.68 | DPP4 (1.00) | DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | DPP4 532/4885DPP8 296/4885DPP9 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.